biostudies-literatureNgeow JIntramural NIH HHS101557https://www.ebi.ac.uk/biostudies/studies/S-EPMC12862869biostudies-literatureUnknown27(11)<h4>Purpose</h4>RAD51C, RAD51D, and BRIP1 germline pathogenic variants (GPVs) are associated with increased lifetime risks of tubo-ovarian cancer. Resources for managing RAD51C, RAD51D, and BRIP1 heterozygotes in clinical practice are limited.<h4>Methods</h4>An international workgroup developed a Clinical Practice Resource to guide management of RAD51C, RAD51D, and BRIP1 heterozygotes using peer-reviewed publications and expert opinion.<h4>Results</h4>RAD51C, RAD51D, and BRIP1 are moderate (intermediate) penetrance ovarian cancer predisposition genes. Ovarian cancer risks for individuals with RAD51C, RAD51D, and BRIP1 GPVs may be influenced by family history and other modifiers. RAD51C and RAD51D GPVs are also associated with moderate risk of breast cancer, predominantly triple-negative suGenetics in medicine : official journal of the American College of Medical GeneticsManagement of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).PMC12862869Z99 CA999999ZIA CP010142Astiazaran-Symonds ELivinski AACass ITischkowitz MHanson HWick MJACMG Professional Practice and Guidelines Committee. Electronic address: documents@acmg.netChiang JStewart DRKlugman SNgeow JFoulkes WDJames PAPal TKatcher ABalmana JKommoss FKFVoian NMak JSfalseManagement of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).<h4>Purpose</h4>RAD51C, RAD51D, and BRIP1 germline pathogenic variants (GPVs) are associated with increased lifetime risks of tubo-ovarian cancer. Resources for managing RAD51C, RAD51D, and BRIP1 heterozygotes in clinical practice are limited.<h4>Methods</h4>An international workgroup developed a Clinical Practice Resource to guide management of RAD51C, RAD51D, and BRIP1 heterozygotes using peer-reviewed publications and expert opinion.<h4>Results</h4>RAD51C, RAD51D, and BRIP1 are moderate (intermediate) penetrance ovarian cancer predisposition genes. Ovarian cancer risks for individuals with RAD51C, RAD51D, and BRIP1 GPVs may be influenced by family history and other modifiers. RAD51C and RAD51D GPVs are also associated with moderate risk of breast cancer, predominantly triple-negative su2025-01-01T00:00:00Z2025 Nov2026-07-14T17:18:00.039Z2026-06-21T03:12:53.605ZS-EPMC128628694107081810.1016/j.gim.2025.101557